Jan Willem de Groot - Concepedia

Author

Jan Willem de Groot

Also Known As

J. GROOT, J. W. De Groot, J. W. de Groot, J.-W. de Groot, J.W. De Groot, J.W. de Groot, JAN WILLEM DE GROOT, Jan W De Groot, Jan W. De Groot, Jan Willem De Groot

114

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Isala University Medical Center Groningen The Netherlands Cancer Institute Radboud University Nijmegen Radboud University Medical Center

About

Jan Willem de Groot is an author at Isala specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	13	237
2	Health Sciences	3	3	152
3	Biochemistry	2	2	29
4	Natural Sciences	1	1	12
5	Allergy	1	1	12

Jan Willem de Groot

Publications

874

Citations

H-Index

Page 1

	Year	Citations
Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10 Karin Frank‐Raue, Lisa Rybicki, Zoran Erlic, Human Mutation	2010	149
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Journal of Clinical Oncology	2022	120
A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients Judith Honing, Justin K. Smit, Christina T. Muijs, Annals of Oncology Esophageal Cancer PatientsEsophageal CancerDefinitive ChemoradiationCancer TreatmentOncology	2014	118
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study Michel Ducreux, Lone Nørgård Pétersen, Leopold Öhler, European Journal of Cancer	2019	75
Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation Karin Frank‐Raue, Nelson Wohllk, Ana Luiza Maia, Endocrine Related Cancer	2008	53
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands Johannes J.M. Kwakman, Geraldine R. Vink, J.H.M.J. Vestjens, International Journal of Clinical Oncology	2017	38
Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with <i>BRAF</i> V600-mutant melanoma. Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Journal of Clinical Oncology Normal Lactate DehydrogenaseImmunologyImmunotherapeuticsDermatologyImmunotherapy	2021	38
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort Marieke S. Walma, L. Brada, Susana I. S. Patuleia, European Journal of Surgical Oncology	2020	34
Optimal regimes for local IL-2 tumour therapy Willem Den Otter, Jan Willem de Groot, Monique R. Bernsen, International Journal of Cancer MedicineImmunologyPharmacologyOptimal RegimesMurine Tumour Models	1996	30
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i>-mutant melanoma. Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Journal of Clinical Oncology Surgical OncologyPart 1Overall SurvivalMedicineMelanoma	2018	30

Page 1